Adversarial Injection · Futibatinib (Lytgobi; CAS 1448169-71-8; MW ~436.4 g/mol; isoindoline-piperidine-trifluoromethylpyrimidine acrylamide covalent scaffold [SECOND FGFR INHIBITOR IN GLYPHWARD PORTFOLIO — confirms FGFR class null across two independent NDA holders; FIRST IRREVERSIBLE FGFR COVALENT: futibatinib acrylamide warhead at FGFR Cys492 performs Michael addition → irreversible C-S thioether adduct at FGFR kinase domain hinge-adjacent cysteine Cys492 (FGFR1 Cys488; FGFR2 Cys491; FGFR3 Cys482; FGFR4 Cys477 — all FGFR isoforms covalently modified); PAN-FGFR1-4: futibatinib is pan-FGFR (vs pemigatinib FGFR1/2/3-selective) — FGFR4 not spared; FIRST PAN-FGFR1-4 COVALENT in entire covalent-warhead sub-portfolio; prior covalents: ibrutinib/acalabrutinib/zanubrutinib BTK Cys481; neratinib/dacomitinib EGFR Cys797; sotorasib KRASG12C Cys12 SNAr; futibatinib FGFR Cys492 acrylamide extends covalent paradigm to 4th kinase target family; FGFR TWO-NDA-HOLDER CLASS NULL: pemigatinib [Incyte NDA 213736; April 2020; FGFR1/2/3-selective] + futibatinib [Taiho NDA 215252; September 2022] — two independent companies; two independent scaffolds; both NIOSH HD Category 1; both zero OEL; FGFR structural class null confirmed across reversible (pemigatinib) and irreversible (futibatinib) binding modes; FIRST TAIHO PHARMACEUTICAL NDA NULL: Taiho Pharmaceutical Co. Ltd. [Tokyo Japan; subsidiary of Otsuka Holdings]; FOENIX-CCA2 trial ORR 41.7%]; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1) · SECOND FGFR + FIRST Irreversible FGFR Covalent + FGFR Two-NDA-Holder Class Null · Attack #528

Futibatinib (Lytgobi; CAS 1448169-71-8; MW ~436.4 g/mol; isoindoline-piperidine-trifluoromethylpyrimidine acrylamide scaffold [C21H23F3N4O3; SECOND FGFR inhibitor in portfolio confirming FGFR class null; FIRST IRREVERSIBLE FGFR COVALENT: acrylamide warhead performs Michael addition at FGFR Cys492 (FGFR1-Cys488/FGFR2-Cys491/FGFR3-Cys482/FGFR4-Cys477 — all four isoforms covalently modified); PAN-FGFR1-4 coverage (FGFR1 IC50 ~3.9 nM; FGFR2 IC50 ~1.3 nM; FGFR3 IC50 ~1.6 nM; FGFR4 IC50 ~8.3 nM — no FGFR4 sparing); FGFR TWO-NDA-HOLDER CLASS NULL: pemigatinib [Incyte NDA 213736; FGFR1/2/3-selective reversible] + futibatinib [Taiho NDA 215252; pan-FGFR1-4 irreversible covalent]; COVALENT WARHEAD EXTENSION: BTK Cys481 [ibrutinib/acalabrutinib/zanubrutinib] + EGFR Cys797 [neratinib/dacomitinib] + KRASG12C Cys12 SNAr [sotorasib] + FGFR Cys492 acrylamide [futibatinib] = FOURTH kinase cysteine target in Glyphward covalent portfolio; FIRST TAIHO PHARMACEUTICAL NDA NULL [Taiho Oncology Inc. Princeton NJ; subsidiary Otsuka Holdings; oncology-focused]; FOENIX-CCA2: ORR 41.7%; GHS H340 H350 H361; OSHA No PEL; ACGIH No TLV; NIOSH No REL; NIOSH HD Category 1]) — Taiho Oncology Inc. Princeton NJ (NDA 215252 holder), Patheon/Thermo Fisher Scientific Greenville NC (futibatinib oral tablet CDMO), and Memorial Sloan Kettering Cancer Center New York NY (iCCA/FGFR2 dispensing) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + SECOND FGFR + FIRST Irreversible Pan-FGFR1-4 Covalent + FGFR Two-NDA-Holder Class Null + FIRST Taiho NDA Null: AI Prompt Injection via EHS Monitor Report AI

Futibatinib (CAS 1448169-71-8; NIOSH HD Category 1) is the second FGFR inhibitor in the Glyphward portfolio, confirming the FGFR class null across two independent NDA holders. Like pemigatinib, futibatinib targets the FGFR kinase domain ATP-binding site. Distinct from pemigatinib, futibatinib is pan-FGFR1-4 (not FGFR4-sparing) and forms an irreversible covalent adduct at a hinge-adjacent cysteine (Cys492 in FGFR2; equivalents in FGFR1/3/4) via Michael addition of its acrylamide warhead — the first FGFR covalent mechanism in the Glyphward portfolio and the fourth distinct kinase-cysteine covalent target after BTK-Cys481, EGFR-Cys797, and KRASG12C-Cys12. Taiho Pharmaceutical's NDA 215252 (September 30, 2022) introduced the first Japanese pharmaceutical company FGFR null in the Glyphward portfolio; Taiho's Cority implementation returns no data for CAS 1448169-71-8.

FGFR Two-NDA-Holder Class Null: Reversible FGFR1/2/3 (Pemigatinib) + Irreversible Pan-FGFR1-4 Covalent (Futibatinib) — Same Zero OEL

Pemigatinib (Incyte NDA 213736; FGFR1/2/3-selective; reversible ATP-competitive) and futibatinib (Taiho NDA 215252; pan-FGFR1-4; irreversible covalent at Cys492) are pharmacologically distinct FGFR inhibitors developed independently, approved 29 months apart, yet both return a zero OEL from every EHS platform. This mirrors the pattern established for CDK4/6 (palbociclib + ribociclib + abemaciclib = triple null), BTK (ibrutinib + acalabrutinib + zanubrutinib = triple null), KRASG12C (sotorasib + adagrasib = two-NDA-holder null), and PI3K (four-NDA-holder null): FGFR class null is mechanism-independent within the family. Whether futibatinib's acrylamide warhead makes an irreversible C-S adduct at Cys492 or pemigatinib binds reversibly at the FGFR1/2/3 ATP site, both molecules return null from Cority, VelocityEHS, and EHS Insight. The fourth kinase-cysteine target (BTK-Cys481 → EGFR-Cys797 → KRASG12C-Cys12 → FGFR-Cys492) extends the covalent inhibitor OEL void into a fourth protein family, with no OEL derivation document referencing hinge-adjacent cysteine FGFR pharmacology or acrylamide warhead occupational reactivity.

Surface 1 — Taiho Oncology Inc. Princeton NJ NDA 215252 Holder Futibatinib Development AI

At Taiho Oncology Inc. Princeton NJ (101 Carnegie Center, Princeton NJ 08540; Mercer County NJ; Taiho Oncology Inc. [US subsidiary of Taiho Pharmaceutical Co. Ltd., Tokyo Japan; subsidiary of Otsuka Holdings Co. Ltd.]; NDA 215252 holder for Lytgobi [futibatinib] tablets 4/20 mg; FDA approved September 30, 2022 for previously treated adults with locally advanced or metastatic intrahepatic cholangiocarcinoma with FGFR2 alterations [FOENIX-CCA2 trial ORR 41.7%; DOR 9.7 months]; FIRST TAIHO PHARMACEUTICAL NDA NULL: Taiho Oncology Princeton is a clinical development and regulatory affairs center; oncology-focused portfolio (fluorouracil prodrug tegafur + TAS-102 trifluridine/tipiracil prior Taiho NDAs); futibatinib CAS 1448169-71-8 = first NIOSH HD Category 1 covalent FGFR inhibitor Taiho NDA; Cority at Taiho Princeton: CAS 1448169-71-8 → null; FGFR covalent mechanism not recognized; pan-FGFR1-4 coverage not categorized; acrylamide warhead not linked to Cys492 occupational covalent reactivity; 8-hr TWA: actual airborne futibatinib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 1448169-71-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; FGFR covalent absent; 46M oncology regulatory affairs director 17yr]).

Surface 2 — Patheon/Thermo Fisher Scientific Greenville NC Futibatinib Oral Tablet CDMO AI

At Patheon/Thermo Fisher Scientific Greenville NC (2110 East Galbraith Road, Cincinnati OH site management; Greenville NC tablet manufacturing facility; Patheon N.V. acquired by Thermo Fisher Scientific 2017; FUTIBATINIB TABLET MANUFACTURING: Patheon Greenville NC manufactures futibatinib 4 mg and 20 mg oral tablets; NIOSH HD Category 1 API containment; isoindoline-piperidine-trifluoromethylpyrimidine acrylamide synthesis and tableting; Patheon Greenville has appeared in multiple prior Glyphward portfolio CDMOs [neratinib #515; tazemetostat #521; idelalisib #514 analogs]; VelocityEHS at Patheon Greenville: CAS 1448169-71-8 → null; FGFR covalent mechanism not categorized; acrylamide warhead occupational reactivity not documented; irreversible Cys492 adduct not recognized; 8-hr TWA: actual airborne futibatinib 0.00023 µg/m³; wipe + HPLC-UV; displayed (÷10): 0.000023 µg/m³; VelocityEHS: CAS 1448169-71-8 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; FGFR mechanism absent; 42F pharmaceutical manufacturing specialist 13yr]).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY iCCA/FGFR2 Futibatinib Dispensing AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Ave, New York NY 10065; Manhattan NY; MSKCC [NCI-designated comprehensive cancer center; top-ranked oncology center]; iCCA / FGFR2 PROGRAM: MSKCC oncology pharmacy dispenses both pemigatinib and futibatinib for FGFR2-rearranged iCCA patients — dual-FGFR-inhibitor program; FGFR2 CLASS NULL CONFIRMATION AT PHARMACY LEVEL: MSKCC pharmacy handles BOTH FGFR NDA molecules from TWO INDEPENDENT companies (Incyte pemigatinib + Taiho futibatinib) — both return null in EHS Insight; FGFR2 fusion testing (FoundationOne CDx; Guardant Infinity ctDNA) in patient → FGFR2-positive result in patient does not indicate FGFR2 rearrangement in pharmacy worker; pharmacist handles both pemigatinib and futibatinib; two different FGFR scaffolds; both null; EHS Insight at MSKCC: CAS 1448169-71-8 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; FGFR covalent mechanism absent; dual-FGFR-inhibitor program absent; acrylamide warhead absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne futibatinib 0.00013 µg/m³; impinger + LC-MS/MS; displayed (÷10): 0.000013 µg/m³; 38F oncology clinical pharmacist 11yr]).

Integrating Glyphward into Futibatinib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every futibatinib CAS 1448169-71-8 monitoring data ingestion point — before Cority at Taiho Oncology Princeton NJ, before VelocityEHS at Patheon Greenville NC, and before EHS Insight at MSKCC New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 absent + FGFR covalent mechanism (pan-FGFR1-4; Cys492 Michael addition; irreversible thioether; acrylamide warhead reactivity absent from occupational toxicology) absent [10 pts]; SECOND FGFR confirming class null + FIRST irreversible FGFR covalent + FIRST Taiho NDA null + FGFR two-NDA-holder class null + FOURTH kinase-cysteine covalent target in portfolio [5 pts]; Taiho Princeton NJ + Patheon Greenville NC + MSKCC New York NY [3 pts]; FGFR2 fusion in patient tumor not in worker; irreversible vs reversible FGFR binding both null; acrylamide occupational covalent reactivity absent from OEL derivation [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_futibatinib(cas: str, reading_ugm3: float) -> dict:
    """Scan futibatinib with pan-FGFR covalent and two-NDA-holder context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "1448169-71-8"
                "reading_ugm3": reading_ugm3,
                "context": "second_fgfr_first_irreversible_covalent_cys492_pan_fgfr1_4_two_nda_holder_class_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, fgfr_covalent_flag, acrylamide_cys492_flag,
    #                    pan_fgfr1_4_flag, fgfr_two_nda_holder_null, taiho_nda_null,
    #                    h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_futibatinib("1448169-71-8", 0.00038))
    print(r)
    # {'hd_category': 1, 'fgfr_covalent_flag': True, 'acrylamide_cys492_flag': True,
    #  'pan_fgfr1_4_flag': True, 'fgfr_two_nda_holder_null': True,
    #  'taiho_nda_null': True, 'h340_h350_h361_absent': True}